loading

You are welcome to send your RFP, feasibility questionnaire or other request at info@mt.clinic

    «BioEq» recruits for patients with nonresectable or metastatic melanoma to participate in a phase II clinical study.

    Study medicationmonoclonal anti-PD-1 antibody.

    Clinical study length: Maximum 69 weeks, including screening (up to 4 weeks), clinical study therapy (up to 53 weeks), further monitoring (up to 12 weeks)

    We invite adult male and female patients with:

    • Histological verificate nonresectable or metastatic melanoma
    • Elementary educed frequent or metastatic melanoma
    • Disease progression after previous system therapy

    Please contact us at 8-812-945-22-32 to learn more.

    1 Comment

    1. Alex

      In test accentus, numquam vocavit, antliam condemnato, sive, exercitatio \’test, quod fit cum ECG est genus exercere.

    Write a Reply or Comment

    Your email address will not be published. Required fields are marked *